The financial situation of Merck's Stocks leaves much room for discussion. Bright prospects and undervaluation have led some investors to view Merck & Co (MRK) as a profitable stock to buy. It remains a favorite among hedge funds and is viewed as a good defensive stock amid market volatility. Despite suffering 27% losses over the past year, Merck (NYSE:MRK) is reportedly growing its earnings, intriguing some savvy investors.
The company's dividend is also noteworthy - it's hailed as a consistent dividend stock and potentially the best healthcare dividend stock, and has been lauded as a very cheap dividend stock. Yet, skeptics highlight the stock's underperformance compared to competitors and the broader market. Recent losses and resultant stock dips have kept interested parties on edge, sparking questions about whether investors should buy, hold, or sell the stock.
There have been a slew of developments too - FDA approved a subcutaneous version of Keytruda, Merck's licensing deal with Chinese biotech for Oral Heart Drug, and a push into China with a $2B Heart Disease Drug Rights Deal. The approval of 21-Valent Pneumococcal Jab Capvaxive from EC adds to these advancements. Despite setbacks, a recent Q4 earnings beat surprised the market.
Merck Stocks News Analytics from Thu, 31 Oct 2024 07:00:00 GMT to Sat, 29 Mar 2025 02:34:40 GMT - Rating 5 - Innovation 7 - Information 6 - Rumor -3
